DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR HALOBETASOL PROPIONATE
» See Plans and Pricing
All Clinical Trials for Halobetasol Propionate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00715975 | Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis | Completed | Azidus Brasil | Phase 2/Phase 3 | 2008-07-01 | The Psoriasis and a chronic dermatosis characterized by abnormal proliferation of cells epithelial, vessel dilation and inflammation locally, which presents erythematous-scaly lesions in various areas of the body, preferably in the scalp, region and religious joints as elbows and knees. It occurs equally in both sexes and can appear at any age, and the mean age for the onset of the disease and around 27.3 years. The halobetasol propionate and an ultra-potent corticoid. Its chemical structure and similar to the Clobetasol corticoid this, until then classified as the most potent corticoid used worldwide in clinical practice. However, the molecular structure of Halobetasol gives it increased its activity antiinflammatory and anti-proliferative. The objective of this study is evaluating the efficacy and tolerability of the drug Halobetasol propionate cream formulation as a treatment in patients with plaque psoriasis mild to moderate, compared to the substance of similar power, Clobetasol propionate - Psorex - Cream. |
| NCT00802958 | Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments | Completed | Perrigo Company | N/A | 2003-07-01 | The purpose of this study was to compare the relative vasoconstrictive effects of test and reference Halobetasol Propionate 0.05% Ointment in healthy, female subjects. |
| NCT00803166 | Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams | Completed | Perrigo Company | N/A | 2004-01-01 | The purpose of this study was to compare the relative vasoconstrictive effects of two test and one reference Halobetasol Propionate 0.05% Cream in healthy, female subjects. |
| NCT00865267 | The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects | Completed | Actavis Inc. | Phase 1 | 2003-12-01 | The purpose of this study is to determine the duration of application of halobetasol propionate 0.05% ointment to be used in a definitive study of bioequivalence of to formulations of this ointment. Part A: To validate vasoconstrictor assay precision. Part B: To evaluate the dose response vasoconstriction profile of Ultravate® 0.05% ointment at different dose durations over a short period of time (0.17 - 4 hrs). |
| NCT00865605 | Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects | Completed | Actavis Inc. | Phase 1 | 2003-12-01 | The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Halobetasol Propionate
Condition Name
Clinical Trial Locations for Halobetasol Propionate
Trials by Country
Clinical Trial Progress for Halobetasol Propionate
Clinical Trial Phase
Clinical Trial Sponsors for Halobetasol Propionate
Sponsor Name
